Mylan and Biocon have announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States. The biosimilar, referencing Herceptin, is now available in a 420-mg multidose vial and a 150-mg single-dose vial.
Mylan and Biocon have announced that their biosimilar trastuzumab, Ogivri, has become commercially available in the United States. The biosimilar, referencing Herceptin, is now available in a 420-mg multidose vial and a 150-mg single-dose vial.
The drug makers did not specify the list price of the biosimilar, but said in a statement that the drug will have a “competitive discount” to its reference “to help ensure access and increase treatment options for patients.” Mylan will offer a full suite of patient services for Ogivri via its Mylan Advocate program, said the companies, and Biocon has sufficient manufacturing capacity to supply both the US market and global markets where the product has already begun to reach patients.
Christiane Hamacher, PhD, chief executive officer of Biocon Biologics, called today’s launch “an important endorsement of our science, development and manufacturing capabilities in the area of monoclonal antibodies. The introduction of both 420mg multi-use vials and 150mg single-use vials of a high quality biosimilar trastuzumab with robust long-term efficacy and safety data will offer greater choice and value to patients, prescribers and [payers] in the US.”
Mylan’s president, Rajiv Malik, added that the biosimilar will “increase more affordable access to this important treatment option for breast and gastric cancer patients. With regulatory approval for our biosimilar trastuzumab in more than 80 countries worldwide, we are bringing vast global biosimilars experience to the US and look forward to continuing our work with all stakeholders in the healthcare system.”
Ogivri was the first biosimilar referencing Herceptin to be approved by the FDA, though it is second to launch, following Amgen’s Kanjinti in July of this year.
Approval of Ogivri was based in part on data from the phase 3 HERITAGE trial, a double-blind, randomized clinical trial that evaluated the biosimilar in patients with HER2-positive metastatic breast cancer without prior chemotherapy or trastuzumab for metastatic disease. In the study, the biosimilar proved to be equivalent to the reference in terms of overall response rate at week 24, and safety was also comparable. Postmarketing data from ex-US territories also support the safety profile of the product, underscoring consistency with the safety profile of the reference trastuzumab.
Ogivri is Mylan and Biocon’s second oncology biosimilar to launch in the United States; first was Fulphila, a pegfilgrastim biosimilar referencing Neulasta, which launched in July 2018 at a 33% discount to its reference.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.